Brief: BioArctic says Rolling Sbla Initiated To U.S. FDA For Leqembi® Iqlik™ As Subcutaneous Starting Dose For Early Alzheimer's Disease Treatment Under Fast Track Status
03/09/2025 04:04
Sept 2 (Reuters) - BioArctic AB BIOAb.ST: ROLLING SBLA INITIATED TO THE U.S. FDA FOR LEQEMBI® IQLIK™ (LECANEMAB-IRMB) AS A SUBCUTANEOUS STARTING DOSE FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE UNDER FAST TRACK STATUS Source text: ID:nPn9nySZFa Further company coverage: [BIOAb.ST] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln